Brought to you by 
Alnylam partners ALNRSV01 with Kyowa in Asia
Jun 2008
Executive Summary
In its second tie-up with a Japanese pharmaco in less than a month, RNA interference specialist Alnylam Pharmaceuticals has granted Kyowa Hakko Kogyo exclusive rights to develop and market its lead therapeutic ALNRSV01 for respiratory syncytial virus (RSV) in Japan and other Asian countries.
Deal Industry
-
Biotechnology
- Antisense, Oligonucleotides
- Large Molecule
- Medical Devices
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
- Nasal
-
Drug Delivery
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Related Companies
Advertisement
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Alnylam partners ALNRSV01 with Kyowa in Asia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice